Incyte Corporation vs Solaris Energy Infrastructure Inc. Class A Common Stock — how do they compare? Incyte Corporation trades at $112 (market cap $22.01B), while Solaris Energy Infrastructure Inc. Class A Common Stock trades at $67 (market cap $5.12B). The key difference: Incyte Corporation is far larger — about 4.3× Solaris Energy Infrastructure Inc. Class A Common Stock's market cap, and Solaris Energy Infrastructure Inc. Class A Common Stock pays a 0.62% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Solaris Energy Infrastructure Inc. Class A Common Stock for 0 Days on average.
| INCY | SEI | |
|---|---|---|
Market Cap | $22.01B | $5.12B |
Volume | 2,589,484 | 2,532,496 |
Sector | Health | Energy |
52-Week High | $129.93 | $82.88 |
52-Week Low | $86.17 | $40.64 |
Typical Hold Time | 33 Days | 0 Days |
Enterprise Value | $17.52B | $6.81B |
Dividend Yield | — | 0.62% |
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $111.57, up 0.19% on the day, with a bearish technical signal but strong fundamentals. Recent earnings beats in Q1 and Q2 2026, with EPS of $1.81 and $3.09 respectively, highlight robust profitability. The company's net income margin improved to 27.71% in 2025, and revenue growth is projected to reach $5.8 billion in 2026. Key developments include FDA approval for Atebrioz and expansion of its inflammation portfolio, supporting long-term growth beyond JAKAFI exclusivity post-2029.
The outlook for INCY is positive, driven by pipeline advancements and a $4 billion sales target for non-JAKAFI products. However, risks include reliance on JAKAFI until 2029 and competitive pressures. Analysts maintain a buy consensus with a $132.43 price target, suggesting ~19% upside. Investors should weigh strong cash flow and valuation metrics against execution risks in pipeline commercialization.
SEI (Solaris Energy Infrastructure) trades at $77.83, down 1.83% today, but maintains strong analyst support with 9 unanimous buy ratings and a $100.56 consensus price target. The stock shows positive momentum with three consecutive quarterly earnings beats and projected revenue growth from $622M in 2025 to $762M in 2026. Recent technical analysis indicates neutral signals with support at $76 and resistance at $79.
The outlook remains positive given strong earnings performance and expansion initiatives, though elevated valuation ratios (P/E of 98.52) and significant debt issuance ($1.25B notes) present risks. The upcoming Q3 2026 earnings report on October 21 will be crucial for validating growth trajectory amid energy sector volatility.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →Solaris Energy Infrastructure, Inc. provides mobile power generation, control, and distribution equipment and logistics equipment for managing raw materials at well sites, operating through its Solaris Power Solutions and Solaris Logistics Solutions segments for data center, energy, commercial, and industrial customers.
Read more on SEI →